X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (53) 53
humans (51) 51
male (48) 48
oncology (41) 41
middle aged (29) 29
adult (28) 28
cancer (22) 22
aged (19) 19
chemotherapy (16) 16
prognosis (16) 16
treatment outcome (16) 16
adolescent (14) 14
antineoplastic agents - therapeutic use (13) 13
immunohistochemistry (13) 13
neoplasm staging (13) 13
female (12) 12
testicular neoplasms - genetics (12) 12
testicular neoplasms - pathology (12) 12
analysis (11) 11
metastasis (11) 11
disease-free survival (9) 9
tumors (9) 9
aged, 80 and over (8) 8
carcinoma, renal cell - drug therapy (8) 8
kidney neoplasms - drug therapy (8) 8
testicular cancer (8) 8
testicular neoplasms - drug therapy (8) 8
urology (8) 8
biomedicine (7) 7
cancer research (7) 7
care and treatment (7) 7
immunology (7) 7
neoplasms, germ cell and embryonal - genetics (7) 7
pathology (7) 7
retrospective studies (7) 7
survival (7) 7
testicular neoplasms - metabolism (7) 7
antineoplastic agents (6) 6
antineoplastic agents - adverse effects (6) 6
cisplatin (6) 6
drug resistance, neoplasm (6) 6
medicine, general & internal (6) 6
metastases (6) 6
patients (6) 6
risk (6) 6
survival analysis (6) 6
testicular neoplasms - diagnosis (6) 6
abiraterone (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
bone neoplasms - secondary (5) 5
carcinoma, renal cell - secondary (5) 5
chemoresistance (5) 5
disease progression (5) 5
drug administration schedule (5) 5
everolimus (5) 5
gene (5) 5
kidney neoplasms - pathology (5) 5
management (5) 5
overexpression (5) 5
prostate cancer (5) 5
prostatic neoplasms, castration-resistant - drug therapy (5) 5
testicular neoplasms - therapy (5) 5
therapy (5) 5
vascular endothelial growth factor (5) 5
antimitotic agents (4) 4
antineoplastic agents - administration & dosage (4) 4
article (4) 4
biomedicine general (4) 4
carcinoma (4) 4
clinical medicine (4) 4
corticosteroids (4) 4
enzalutamide (4) 4
europe (4) 4
expression (4) 4
genetic aspects (4) 4
genetic predisposition to disease (4) 4
genetics & heredity (4) 4
germinoma - pathology (4) 4
hungary (4) 4
immunotherapy (4) 4
kaplan-meier estimate (4) 4
kidney cancer (4) 4
medical research (4) 4
neoplasms, germ cell and embryonal - drug therapy (4) 4
neoplasms, germ cell and embryonal - pathology (4) 4
population (4) 4
prostate-specific antigen - blood (4) 4
prostatic neoplasms, castration-resistant - pathology (4) 4
research (4) 4
sunitinib (4) 4
survival rate (4) 4
testicular neoplasms (4) 4
tyrosine kinase inhibitors (4) 4
urology & nephrology (4) 4
abridged index medicus (3) 3
anemia (3) 3
antineoplastic agents - pharmacology (3) 3
apoptosis (3) 3
biomarkers (3) 3
biomarkers, tumor - blood (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1989, Új magyar népköltési gyűjtemény, ISBN 9789630548120, Volume 23, 611
Book
The New England Journal of Medicine, ISSN 0028-4793, 11/2015, Volume 373, Issue 19, pp. 1814 - 1823
Journal Article
1992, 1. kiad., Témakör, ISBN 8070891548, Volume 13, 240
Book
by Petrylak, Daniel and Petrylak, Daniel P and de Wit, Ronald and Chi, Kim Nguyen and Chi, Kim N and Drakaki, Alexandra and Sternberg, Cora N and Nishiyama, Hiroyuki and Castellano, Daniel and Hussain, Syed and Fléchon, Aude and Bamias, Aristotelis and Yu, Evan Y and van der Heijden, Michiel S and Matsubara, Nobuaki and Alekseev, Boris and Necchi, Andrea and Géczi, Lajos and Ou, Yen-Chuan and Coskun, Hasan Senol and Su, Yu-Li and Su, Wen-Pin and Hegemann, Miriam and Percent, Ivor and Percent, Ivor J and Lee, Yun-Gyoo and Lee, Hyo Jin and Lee, Jae-Lyun and Tucci, Marcello and Semenov, Andrey and Laestadius, Fredrik and Peer, Avivit and Tortora, Giampaolo and Safina, Sufia Z and Safina, Sufia and del Muro, Xavier Garcia and Rodriguez-Vida, Alejo and Cicin, Irfan and Harputluoglu, Hakan and Widau, Ryan C and Liepa, Astra M and Walgren, Richard A and Hamid, Oday and Zimmermann, Annamaria H and Bell-McGuinn, Katherine M and Powles, Thomas and Wong, Suet-Lai Shirley and Tan, Thean Hsiang and Hovey, Elizabeth Jane and Clay, Timothy Dudley and Ng, Siobhan Su Wan and Rutten, Annemie and Machiels, Jean-Pascal and Dumez, Herlinde and Cheng, Susanna Yee-Shan and Ferrario, Cristiano and Sengeloev, Lisa and Jensen, Niels Viggo and Thibault, Constance and Laguerre, Brigitte and Joly, Florence and Flechon, Aude and Culine, Stéphane and Becht, Catherine and Niegisch, Günter and Stöckle, Michael and Grimm, Marc-Oliver and Gakis, Georgios and Schultze-Seemann, Wolfgang and Kalofonos, Haralambos and Mavroudis, Dimitrios and Papandreou, Christos and Karavasilis, Vasilis and Révész, Janos and Geczi, Lajos and Rosenbaum, Eli and Leibowitz-Amit, Raya and Kejzman, Daniel and Sarid, David and Scagliotti, Giorgio Vittorio and Bracarda, Sergio and Massari, Francesco and Osawa, Takahiro and Miyajima, Naoto and Shinohara, Nobuo and Fukuta, Fumimasa and Ohyama, Chikara and Obara, Wataru and Yamashita, Shinichi and Tomita, Yoshihiko and Kawai, Koji and Fukasawa, Satoshi and Oyama, Masafumi and Yonese, Junji and Nagata, Masayoshi and Uemura, Motohide and Nishimura, Kazuo and Kawakita, Mutsushi and Tsunemori, Hiroyuki and Hashine, Katsuyoshi and ... and RANGE Study Investigators and RANGE study investigators
The Lancet, ISSN 0140-6736, 11/2017, Volume 390, Issue 10109, pp. 2266 - 2277
Few treatments with a distinct mechanism of action are available for patients with platinum-refractory advanced or metastatic urothelial carcinoma. We assessed... 
BLADDER-CANCER | MEDICINE, GENERAL & INTERNAL | 2ND-LINE THERAPY | TRANSITIONAL-CELL-CARCINOMA | CISPLATIN | DOXORUBICIN | METHOTREXATE | VINBLASTINE | OPEN-LABEL | COMBINATION | ENDOTHELIAL GROWTH-FACTOR | Carcinoma, Transitional Cell - mortality | Prognosis | Humans | Middle Aged | Male | Neoplasm Invasiveness - pathology | Urinary Bladder Neoplasms - pathology | Adult | Female | Urinary Bladder Neoplasms - mortality | Double-Blind Method | Risk Assessment | Docetaxel | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Urinary Bladder Neoplasms - drug therapy | Disease-Free Survival | Taxoids - administration & dosage | Carcinoma, Transitional Cell - pathology | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Internationality | Neoadjuvant Therapy - methods | Carcinoma, Transitional Cell - drug therapy | Survival Analysis | Aged | Neoplasm Staging | Antimitotic agents | Care and treatment | Carcinoma | Analysis | Clinical trials | Product development | Metastasis | Antineoplastic agents | Cancer | Cytotoxicity | Oncology | Patients | Cancer therapies | Metastases | Angiogenesis | Chemotherapy | Platinum | Medical prognosis | Ligands | Clinical medicine | Urothelial carcinoma | Vascular endothelial growth factor | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Magyar onkologia, ISSN 0025-0244, 03/2019, Volume 63, Issue 1, pp. 60 - 64
As a result of the growing incidence of cancer as well as increased survival of patients, an increasing number of people are living longer with cancer. In... 
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1263 - 1268
Journal Article
1990, ISBN 9789634821380, v. <1-14, 17, 22, 23-24, 26-27, 31>
Book
Magyar onkologia, ISSN 0025-0244, 06/2017, Volume 61, Issue 2, pp. 139 - 146
By the emergence of modern immunotherapies with active agents like PD-1 (nivolumab, pembrolizumab) and PD-L1 immune checkpoint blockers (atezolizumab,... 
Journal Article
Journal Article
Clinical Drug Investigation, ISSN 1173-2563, 6/2019, Volume 39, Issue 6, pp. 577 - 583
Sunitinib is still one of the standard therapies in metastatic renal cell carcinoma (mRCC). Despite the benefit of sunitinib resistance will develop in the... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Kidney cancer | Regression analysis | Metastasis | Clinical medicine | Patients | Vascular endothelial growth factor | Cancer therapies | Tumors | Short Communication
Journal Article
Magyar onkologia, ISSN 0025-0244, 03/2019, Volume 63, Issue 1, pp. 33 - 39
During the last decades androgen deprivation therapy (ADT) was the standard treatment of prostate cancers. Survival of metastatic patients is 4 years if they... 
Journal Article
Magyar onkologia, ISSN 0025-0244, 03/2019, Volume 63, Issue 1, pp. 33 - 39
Journal Article
Journal Article
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.